Medications for Parkinson's disease.
Whitney
Christina M
CM
Neurological Institute, Movement Disorders Center, University Hospitals Case Medical Center, Cleveland, Ohio.
D000547:Amantadine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D011954:Receptors, Dopamine; D000547:Amantadine; D004298:Dopamine